Aliqopa (Copanlisib) for Lymphoma

Overview
Aliqopa was a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed follicular lymphoma. Aliqopa was withdrawn from the market in November 2023. Aliqopa was indicated in cases where at least two previous therapies have been tried. Aliqopa is also referred to by its drug name, copanlisib.

Aliqopa is a member of a class of drugs called kinase inhibitors. Aliqopa was believed to work by inhibiting replication and triggering cell death in lymphoma cells.

How do I take it?
Prescribing information stated that Aliqopa was given as an intravenous injection on three specific days in a 28-day cycle.

Aliqopa came in the form of a single-use vial.

Side effects
The FDA-approved label for Aliqopa listed common side effects including high blood sugar, diarrhea, decreased general strength and energy, high blood pressure, low blood cell counts, nausea, and lower respiratory tract infections.

Rare but serious side effects listed for Aliqopa included severe skin reactions, pneumonitis (lung inflammation), severe high blood pressure, and fetal harm in pregnant women.

For more details about this treatment, visit:

Aliqopa — Bayer
www.hcp.aliqopa-us.com

Treatment for Indolent NHL Subtypes — Leukemia & Lymphoma Society
www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-s...

Bayer Withdraws Follicular Lymphoma Drug After Further Trial Fails —Reuters
https://www.reuters.com/business/healthcare-pha...